Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
Background. Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2020/8834148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566040177934336 |
|---|---|
| author | G. Rendl B. Sipos A. Becherer S. Sorko C. Trummer M. Raderer W. Hitzl M. Ardelt H. J. Gallowitsch C. Pirich |
| author_facet | G. Rendl B. Sipos A. Becherer S. Sorko C. Trummer M. Raderer W. Hitzl M. Ardelt H. J. Gallowitsch C. Pirich |
| author_sort | G. Rendl |
| collection | DOAJ |
| description | Background. Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (PFS) and tolerability in the Austrian patient population treated with lenvatinib. Methods. Clinical data of 43 patients (25 males and 18 females) with a median age of 70 years (range: 39–91 years) and RAI-refractory TC with metastases to the lymph nodes (74%), lungs (86%), bone (35%), liver (16%), and brain (12%) were analyzed. The mean duration of treatment with lenvatinib was 26.6 ± 15.4 months with dosage reductions required in 39 patients (91%). Results. PFS after 24 months was 71% (95% CI: 56–87), and overall survival (OS) was 74% (95% CI: 60–88), respectively. OS was significantly shorter (p=0.048) in patients with a daily maintenance dosage ≤ 10 mg (63%) (95% CI: 39–86) as compared to patients on ≥ 14 mg lenvatinib (82%) (95% CI: 66–98) daily. Dose reduction was noted in 39 patients (91%). Grade ≥3 toxicities (hypertension, diarrhea, weight loss, and palmar-plantar erythrodysesthesia syndrome) were most common leading to discontinuation of lenvatinib in 7 patients (16%). Conclusion. Lenvatinib showed sustained clinical efficacy in patients with metastatic RAI-refractory TC even with reduced maintenance dosages over years. The effects were comparable to the registration trial, although patients had a higher median age and, more commonly, dose reductions. |
| format | Article |
| id | doaj-art-045a596d980449e9b5e20e1195082027 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-045a596d980449e9b5e20e11950820272025-02-03T01:05:10ZengWileyInternational Journal of Endocrinology1687-83371687-83452020-01-01202010.1155/2020/88341488834148Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in AustriaG. Rendl0B. Sipos1A. Becherer2S. Sorko3C. Trummer4M. Raderer5W. Hitzl6M. Ardelt7H. J. Gallowitsch8C. Pirich9Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, AustriaDepartment of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, AustriaDepartment of Nuclear Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, AustriaDepartment of Nuclear Medicine and Endocrinology, PET/CT Centre, Klinikum Klagenfurt am Wörthersee, Klagenfurt, AustriaDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaDepartment of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaResearch Office (Biostatistics), Paracelsus Medical University Salzburg, Salzburg, AustriaInstitute of Pharmacy, Paracelsus Medical University Salzburg, Salzburg, AustriaDepartment of Nuclear Medicine and Endocrinology, PET/CT Centre, Klinikum Klagenfurt am Wörthersee, Klagenfurt, AustriaDepartment of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, AustriaBackground. Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (PFS) and tolerability in the Austrian patient population treated with lenvatinib. Methods. Clinical data of 43 patients (25 males and 18 females) with a median age of 70 years (range: 39–91 years) and RAI-refractory TC with metastases to the lymph nodes (74%), lungs (86%), bone (35%), liver (16%), and brain (12%) were analyzed. The mean duration of treatment with lenvatinib was 26.6 ± 15.4 months with dosage reductions required in 39 patients (91%). Results. PFS after 24 months was 71% (95% CI: 56–87), and overall survival (OS) was 74% (95% CI: 60–88), respectively. OS was significantly shorter (p=0.048) in patients with a daily maintenance dosage ≤ 10 mg (63%) (95% CI: 39–86) as compared to patients on ≥ 14 mg lenvatinib (82%) (95% CI: 66–98) daily. Dose reduction was noted in 39 patients (91%). Grade ≥3 toxicities (hypertension, diarrhea, weight loss, and palmar-plantar erythrodysesthesia syndrome) were most common leading to discontinuation of lenvatinib in 7 patients (16%). Conclusion. Lenvatinib showed sustained clinical efficacy in patients with metastatic RAI-refractory TC even with reduced maintenance dosages over years. The effects were comparable to the registration trial, although patients had a higher median age and, more commonly, dose reductions.http://dx.doi.org/10.1155/2020/8834148 |
| spellingShingle | G. Rendl B. Sipos A. Becherer S. Sorko C. Trummer M. Raderer W. Hitzl M. Ardelt H. J. Gallowitsch C. Pirich Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria International Journal of Endocrinology |
| title | Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria |
| title_full | Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria |
| title_fullStr | Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria |
| title_full_unstemmed | Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria |
| title_short | Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria |
| title_sort | real world data for lenvatinib in radioiodine refractory differentiated thyroid cancer relevant a retrospective multicentric analysis of clinical practice in austria |
| url | http://dx.doi.org/10.1155/2020/8834148 |
| work_keys_str_mv | AT grendl realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT bsipos realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT abecherer realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT ssorko realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT ctrummer realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT mraderer realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT whitzl realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT mardelt realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT hjgallowitsch realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria AT cpirich realworlddataforlenvatinibinradioiodinerefractorydifferentiatedthyroidcancerrelevantaretrospectivemulticentricanalysisofclinicalpracticeinaustria |